These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18786011)

  • 1. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
    Gröner A
    Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
    Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
    Carter NJ; Scott LJ
    Drugs; 2007; 67(10):1513-9. PubMed ID: 17600395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemate P/Humate-P: a systematic review.
    Berntorp E
    Thromb Res; 2009 Nov; 124 Suppl 1():S11-4. PubMed ID: 19944255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
    Schramm W
    Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P
    de Jager NCB; Bukkems LH; Heijdra JM; Hazendonk CHCAM; Fijnvandraat K; Meijer K; Eikenboom J; Laros-van Gorkom BAP; Leebeek FWG; Cnossen MH; Mathôt RAA;
    J Thromb Haemost; 2020 Feb; 18(2):295-305. PubMed ID: 31557387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.
    Kouides P; Wawra-Hehenberger K; Sajan A; Mead H; Simon T
    Transfusion; 2017 Oct; 57(10):2390-2403. PubMed ID: 28691218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
    Federici AB; Mannucci PM
    Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis E virus: Efficacy of pasteurization of plasma-derived VWF/FVIII concentrate determined by pig bioassay.
    Dähnert L; Schlosser J; Fast C; Fröhlich A; Gröner A; Lange E; Roth NJ; Schäfer W; Schröder C; Eiden M; Groschup MH
    Transfusion; 2021 Apr; 61(4):1266-1277. PubMed ID: 33605455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.
    Metzner HJ; Hermentin P; Cuesta-Linker T; Langner S; Müller HG; Friedebold J
    Haemophilia; 1998; 4 Suppl 3():25-32. PubMed ID: 10028315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.